" class="no-js "lang="en-US"> Roel Gordijn - Medtech Alert
Wednesday, August 13, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Roel Gordijn

Roel Gordijn

About Roel Gordijn

Roel Gordijn is the Chief Commercial Officer at Polyplus-transfection®. Previously he was the General Manager of the Gene-Therapy business at Pall Biotech. Before that Roel has managed the Global Commercial Integrated Solutions, Strategic Account Management and Single Use technology teams at Pall and the Global Industrial Cell Culture Media Sales and Marketing teams at Lonza.

Related Story

Industry News

 Exothera Announces Industrial Scale AAV Manufacturing Collaboration With LogicBio Therapeutics and Polyplus | Pharmtech Focus

Exothera Announces Industrial Scale AAV Manufacturing Collaboration With LogicBio Therapeutics and Polyplus

June 15 2022

Exothera SA today announced a collaboration with LogicBio® Therapeutics and Polyplus-transfection® SA. for the development of […]